Coordinatore | LATVIJAS ORGANISKAS SINTEZES INSTITUTS
Organization address
address: AIZKRAUKLES 21 contact info |
Nazionalità Coordinatore | Latvia [LV] |
Totale costo | 5˙262˙038 € |
EC contributo | 4˙707˙491 € |
Programma | FP7-REGPOT
Specific Programme "Capacities": Research potential of Convergence Regions |
Code Call | FP7-REGPOT-2012-2013-1 |
Funding Scheme | CSA-SA |
Anno di inizio | 2013 |
Periodo (anno-mese-giorno) | 2013-09-01 - 2017-02-28 |
# | ||||
---|---|---|---|---|
1 |
LATVIJAS ORGANISKAS SINTEZES INSTITUTS
Organization address
address: AIZKRAUKLES 21 contact info |
LV (RIGA) | coordinator | 4˙707˙491.00 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
'The general objectives of the InnovaBalt project are to improve multidisciplinary research capacities and strengthen the management of intellectual property and human resources for innovative drug discovery at the Latvian Institute of Organic Synthesis (LIOS). LIOS is the leading regional research centre for drug discovery, which consists of organic synthesis, medicinal chemistry and the pharmaceutical development of compounds designed for the treatment of cancer, cardiovascular diseases and CNS disorders. LIOS has a clear vision of its mission, which is to develop sustained research activities in the domain of innovative medicine. The following objectives will be implemented: 1. Long-lasting scientific collaboration and strategic partnerships between LIOS and 50 outstanding research institutions will be established and sustained to increase the visibility of LIOS in the European Research Area (ERA); 2. The management of intellectual property will be improved and innovation will be increased by collaborating with and attracting 14 external professionals; 3. The research infrastructure and qualification of human resources at LIOS will be upgraded in the fields of modern process chemistry, green chemistry, biophysical chemistry, in silico drug discovery, advanced forms for drug delivery and research and innovation management to promote the capacity for high-level research on innovative drug development; 4. Synergy between research on innovative drug development and end-users will be ensured to meet the socio-economic needs of the Baltic region. The implementation of the aforementioned objectives will reinforce the strategic development of LIOS, improve the scientific outcomes and promote the long-term impact of the LIOS research through its wholesome integration into the ERA.'